RBC Capital's Jason Kantor weighs in on the news that Seattle Genetics (SGEN -0.3%) scored a...

|About: Seattle Genetics, Inc. (SGEN)|By:, SA News Editor

RBC Capital's Jason Kantor weighs in on the news that Seattle Genetics (SGEN -0.3%) scored a victory with testing of its Adcetris drug for Hodgkin lymphoma, and is closing in on Phase III trials. The analysts say that if the drug becomes part of first-line treatment, it would "significantly increase" the target population for it by 4X-5X. "Most doctors we talk to believe Adcetris will ultimately become part of standard of care."